Lung Cancer | Specialty

Japanese Approval Sought for Frontline Osimertinib in NSCLC

November 27th 2017

A sNDA has been submitted to Japan’s Pharmaceuticals and Medical Devices Agency for the use of osimertinib (Tagrisso) as a frontline treatment for patients with inoperable or recurrent EGFR-positive NSCLC.

Immunotherapy to Have Emerging Role in Squamous Cell Lung Cancer

November 22nd 2017

George R. Blumenschein, MD, discusses the current treatment landscape for patients with squamous cell lung cancer.

Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

November 22nd 2017

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval

November 21st 2017

The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Dr. Induru Discusses Other Mutations in Lung Cancer

November 21st 2017

Raghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.

Update Sustains Osimertinib Activity Against CNS Mets in NSCLC

November 21st 2017

New results again demonstrated the benefit of frontline osimertinib in patients with EGFR-positive advanced non-small cell lung cancer and CNS metastases at baseline.

Atezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC

November 20th 2017

The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Dr. Weiss Discusses When to Biopsy in Lung Cancer

November 18th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses how and when to biopsy patients for lung cancer.

Dr. Heinzerling on Remaining Challenges for Treating NSCLC

November 17th 2017

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses remaining challenges for treating stage III non–small cell lung cancer (NSCLC).

Canadian Research Leader Makes Worldwide Impact on Lung Cancer

November 15th 2017

Frances A. Shepherd, MD, has spent more than 3 decades demonstrating that medical oncology can help patients with lung cancer during all stages of their journey.

Dr. Mott on Sequencing of Treatments with NSCLC

November 15th 2017

Frank E. Mott, MD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the sequencing of treatments for patients with non-small cell lung cancer (NSCLC).

Ramalingam Expands on Osimertinib Updates in NCCN Guidelines for EGFR+ NSCLC

November 14th 2017

Suresh A. Ramalingam, MD, discusses some of the changes to the NCCN guidelines in non-small cell lung cancer, specifically with EGFR-mutation–positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017